Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Multiple Myeloma
Multiple Myeloma for November/December 2017
Cochrane on Bisphosphonates in Multiple Myeloma, Cochrane; 2017 Dec 18; Mhaskar, Kumar, et al
VDT PACE-Like Therapy for Relapsed/Refractory MM, Am J Hematol; ePub 2017 Nov 10; Lakshman, et al
Auto/Allo and Tandem Auto HCT for MM Compared, Biol Blood Marrow Transplant; ePub 2017 Oct 25; Htut, et al
Multiple Myeloma for September/October 2017
Index Can Predict Survival in Patients with MM, Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 19; Ely, et al
Multiple Myeloma for July/August 2017
Economic Burden of Multiple Myeloma Evaluated, Leuk Lymphoma; ePub 2017 Aug 13; MacEwan, et al
Lenalidomide After ASCT for Multiple Myeloma, J Clin Oncol; ePub 2017 Jul 25; McCarthy, et al
Toxicity and Mortality in Older AHCT Recipients, Am J Hematol; ePub 2017 Jul 19; Belete, et al
FDA Approves Test to Detect Cancerous Cells in Blood, FDA news release; 2017 Jun 29
Multiple Myeloma for May/June 2017
Auto-HCT in Refractory Multiple Myeloma, Cancer; ePub 2017 May 17; Veltri, Milton, et al
Multiple Myeloma for March/April 2017
Post-Auto HSCT Mortality in Elderly with MM , Biol Blood Marrow Transplant; ePub 2017 Mar 9; Sanchez, et al
Revlimid Indication Expanded, Celgene news release; 2017 Feb 22
